Beyond its effects on phagocytes, anti-CD47 treatment was found to modulate the tumor microenvironment to be more permissive for anti-tumor T cells in preclinical models of head and neck squamous cell carcinoma [71]. The gene discussed is CD47; the disease is neoplasm.